Clik here to view.
MIQE compliance in expression profiling and clinical biomarker discovery
Molecular diagnostics and biomarker discovery are gaining increasing attraction in clinical research. This includes all fields of diagnostics, such as risk assessment, disease prognosis, treatment...
View ArticleClik here to view.
First patient enrolled in IPF biomarker study of Ofev
The first patient has been enrolled in INMARK – a study investigating the effect of Boehringer Ingelhiem’s Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic...
View ArticleClik here to view.
Biomarker breakthrough could improve Parkinson’s treatment
Scientists have found that using magnetic resonance imaging reveals areas where Parkinson’s disease causes progressive decline in brain activity, a biomarker discovery which will help to evaluate new...
View ArticleClik here to view.
FDA approves Roche’s immunotherapy assay to support treatment decisions in...
The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for...
View ArticleClik here to view.
Dolomite Bio’s Single Cell RNA-Seq System accelerating cancer research
Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance...
View ArticleClik here to view.
Biocartis and Merck partnership launch second liquid biopsy assay
Biocartis and Merck have launched the Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only). Being the third liquid biopsy test for Biocartis, the newly launched assay also marks an...
View ArticleClik here to view.
GeNeuro initiates Phase 2a study in Australia to treat Type 1 Diabetes
GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, have started a Phase 2a clinical study in Australia with GNbAC1 in patients with Type...
View ArticleClik here to view.
BMS Phase II study in non-alcoholic steatohepatitis a success
BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis,...
View ArticleClik here to view.
Roche receives FDA approval for bladder cancer biomarker assay
The US Food and Drug Administration (FDA) has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with locally advanced or metastatic urothelial...
View ArticleClik here to view.
FDA approves first cancer treatment for any solid tumor with a specific...
The US Food and Drug Administration (FDA) granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has...
View Article
